Study ID,Study,Experiment Name,Experiment Notes,Strain Ont ID,Strain,Sex,Age,# of Animals,Sample Notes,Clinical Measurement Ont ID,Phenotype,Formula,Clinical Measurement Notes,Average Type,Value,Units,SEM,SD,Method Ont ID,Method,Method Site,Method Duration,Method Notes,Post Insult Type,Post Insult Time Value,Post Insult Time Unit,Conditions,Record ID,Condition 1,Condition 2a,Condition 2b,Condition 3 1096,"Dutil J, et al., Physiol Genomics 2005 Mar 1;.",vasoconstriction trait,,RS:0000817,SS/Jr,male,98 days,12,,CMO:0000716,blood vessel contractile force measurement,,,,1.39,g,0.06,0.2078,MMO:0000207,tissue force analysis utilizing a force transducer,,0.0,isometric force transducer,,,,Kreb's solution perfusate then potassium chloride solution (40 mmol/l) and NG-nitroarginine methyl ester (100 umol/l) ,69050,Kreb's solution perfusate,potassium chloride solution (40 mmol/l) ,NG-nitroarginine methyl ester (100 umol/l) , 1096,"Dutil J, et al., Physiol Genomics 2005 Mar 1;.",vasoconstriction trait,,RS:0000817,SS/Jr,male,98 days,12,,CMO:0000716,blood vessel contractile force measurement,,,,1.59,g,0.11,0.3811,MMO:0000207,tissue force analysis utilizing a force transducer,,0.0,,,,,Kreb's solution perfusate then potassium chloride solution (40 mmol/l) ,69048,Kreb's solution perfusate,potassium chloride solution (40 mmol/l) ,, 1096,"Dutil J, et al., Physiol Genomics 2005 Mar 1;.",vasoconstriction trait,,RS:0000817,SS/Jr,male,98 days,12,,CMO:0000722,logarithm of the concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (Log EC50),,EC50 value is probably moles/liter,,-7.6,,0.05,0.1732,MMO:0000207,tissue force analysis utilizing a force transducer,,0.0,isometric force transducer,,,,Kreb's solution perfusate then phenylephrine (1~100 mmol/l) and NG-nitroarginine methyl ester (100 umol/l) ,69058,Kreb's solution perfusate,phenylephrine (1~100 mmol/l) ,NG-nitroarginine methyl ester (100 umol/l) , 1096,"Dutil J, et al., Physiol Genomics 2005 Mar 1;.",vasoconstriction trait,,RS:0000817,SS/Jr,male,98 days,12,,CMO:0000722,logarithm of the concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (Log EC50),,EC50 value is probably moles/liter,,-7.26,,0.06,0.2078,MMO:0000207,tissue force analysis utilizing a force transducer,,0.0,isometric force transducer,,,,Kreb's solution perfusate then phenylephrine (1~100 mmol/l) ,69054,Kreb's solution perfusate,phenylephrine (1~100 mmol/l) ,, 1096,"Dutil J, et al., Physiol Genomics 2005 Mar 1;.",vasoconstriction trait,,RS:0000817,SS/Jr,male,98 days,12,,CMO:0001656,receptor-dependent blood vessel maximum contractile force to receptor-independent blood vessel maximum contractile force ratio,,,,141.72,%,7.73,26.7775,MMO:0000207,tissue force analysis utilizing a force transducer,,0.0,isometric force transducer,,,,Kreb's solution perfusate then phenylephrine (1~100 mmol/l) and NG-nitroarginine methyl ester (100 umol/l) ,69056,Kreb's solution perfusate,phenylephrine (1~100 mmol/l) ,NG-nitroarginine methyl ester (100 umol/l) , 1096,"Dutil J, et al., Physiol Genomics 2005 Mar 1;.",vasoconstriction trait,,RS:0000817,SS/Jr,male,98 days,12,,CMO:0001656,receptor-dependent blood vessel maximum contractile force to receptor-independent blood vessel maximum contractile force ratio,,,,104.06,%,4.7,16.2813,MMO:0000207,tissue force analysis utilizing a force transducer,,0.0,isometric force transducer,,,,Kreb's solution perfusate then phenylephrine (1~100 mmol/l) ,69052,Kreb's solution perfusate,phenylephrine (1~100 mmol/l) ,, 1096,"Dutil J, et al., Physiol Genomics 2005 Mar 1;.",vasoconstriction trait,,RS:0000817,SS/Jr,male,98 days,12,,CMO:0001656,receptor-dependent blood vessel maximum contractile force to receptor-independent blood vessel maximum contractile force ratio,,,,50.61,%,5.29,18.3251,MMO:0000207,tissue force analysis utilizing a force transducer,,0.0,isometric force transducer,,,,Kreb's solution perfusate then angiotensin II (0.3~300 umol/l) and NG-nitroarginine methyl ester (100 umol/l) ,69069,Kreb's solution perfusate,angiotensin II (0.3~300 umol/l) ,NG-nitroarginine methyl ester (100 umol/l) , 1096,"Dutil J, et al., Physiol Genomics 2005 Mar 1;.",vasoconstriction trait,,RS:0000817,SS/Jr,male,98 days,12,,CMO:0001656,receptor-dependent blood vessel maximum contractile force to receptor-independent blood vessel maximum contractile force ratio,,,,34.85,%,2.94,10.1845,MMO:0000207,tissue force analysis utilizing a force transducer,,0.0,isometric force transducer,,,,Kreb's solution perfusate then angiotensin II (0.3~300 umol/l) ,69065,Kreb's solution perfusate,angiotensin II (0.3~300 umol/l) ,, 1096,"Dutil J, et al., Physiol Genomics 2005 Mar 1;.",vasoconstriction trait,,RS:0000817,SS/Jr,male,98 days,12,,CMO:0001658,logarithm of the concentration of angiotensin II at which the force of blood vessel contraction is half the maximum value (Log EC50),,,,-7.92,,0.36,1.2471,MMO:0000207,tissue force analysis utilizing a force transducer,,0.0,isometric force transducer,,,,Kreb's solution perfusate then angiotensin II (0.3~300 umol/l) then NG-nitroarginine methyl ester (100 umol/l) ,69071,Kreb's solution perfusate,angiotensin II (0.3~300 umol/l) ,,NG-nitroarginine methyl ester (100 umol/l) 1096,"Dutil J, et al., Physiol Genomics 2005 Mar 1;.",vasoconstriction trait,,RS:0000817,SS/Jr,male,98 days,12,,CMO:0001658,logarithm of the concentration of angiotensin II at which the force of blood vessel contraction is half the maximum value (Log EC50),,,,-8.22,,0.26,0.9007,MMO:0000207,tissue force analysis utilizing a force transducer,,0.0,isometric force transducer,,,,Kreb's solution perfusate then angiotensin II (0.3~300 umol/l) ,69067,Kreb's solution perfusate,angiotensin II (0.3~300 umol/l) ,,